(Q27852112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Giovanni Pellacani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Aldo Tomasi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Andrea Spallanzani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Stefania Borsari

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Andrea Conti

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Fabio Gelsomino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Roberta Depenni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Samer Al Jalbout

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Lisa Simi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Lorella Garagnani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Cristel Ruini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Annalisa Fontana

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Gabriele Luppi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

5 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pathology

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

441-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

25 February 2020

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE09626

Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

The role of BRAF V600 mutation in melanoma

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Targeting BRAF in advanced melanoma: a first step toward manageable disease

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Rituximab and statins

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

BRAF mutations in advanced cancers: clinical characteristics and outcomes

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

25 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1136/JCLINPATH-2012-201345

Identifiers

DOI

10.1136/JCLINPATH-2012-201345

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23463675%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

2 references

13 November 2016